When it comes to SLC2A3, a recent study observed that SLC2A3 knockdown significantly inhibited the expression of PD-L1 indicating SLC2A3 could participate in the immune response by regulating the PD-L1 immune checkpoint in CRC [10]. This evidence concerns the gene SLC2A3 and colorectal carcinoma.